This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

New Horizon Health Valuation

Q: What is the Fair Price of 6606 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6606 (HK$14.14) is trading below our estimate of [[fair value]] (HK$119.06)

Is 6606 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6606 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6606 (HK$14.14) is trading below our estimate of fair value (HK$119.06)

Significantly Below Fair Value: 6606 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6606?

Key metric: As 6606 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6606. This is calculated by dividing 6606's market cap by their current earnings.
What is 6606's PE Ratio?
PE Ratio	52.8x
Earnings	CN¥111.70m
Market Cap	CN¥5.90b

6606 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.4x
Enterprise Value/EBITDA	-46.2x
PEG Ratio	0.9x

Price to Earnings Ratio vs Peers

How does 6606's PE Ratio compare to its peers?

The above table shows the PE ratio for 6606 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	836.1x
1951 Jinxin Fertility Group	24.2x	19.4%	HK$8.0b
2273 Gushengtang Holdings	29.3x	32.8%	HK$8.2b
9860 Adicon Holdings	24x	20.2%	HK$4.6b
2522 Jiangxi Rimag Group	3266.8x	71.8%	HK$18.1b
6606 New Horizon Health	52.8x	60.4%	HK$6.3b

Price-To-Earnings vs Peers: 6606 is good value based on its Price-To-Earnings Ratio (52.8x) compared to the peer average (57.6x).

Price to Earnings Ratio vs Industry

How does 6606's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
574 Pa Shun International Holdings	1.9x	n/a	US$8.72m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 6606 is expensive based on its Price-To-Earnings Ratio (52.8x) compared to the Hong Kong Healthcare industry average (12.3x).

Price to Earnings Ratio vs Fair Ratio

What is 6606's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6606 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	52.8x
Fair PE Ratio	42.8x

Price-To-Earnings vs Fair Ratio: 6606 is expensive based on its Price-To-Earnings Ratio (52.8x) compared to the estimated Fair Price-To-Earnings Ratio (42.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$10.0b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.12

-5.8%

-67.0%

Hygeia Healthcare Holdings

HK$10.0b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.12

-5.8%

-67.0%

Sinopharm Group

HK$64.3b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.60

-0.2%

6.1%